6-(aminomethyl)-1,2,4-triazin-5(4H)-one | 867163-25-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-(aminomethyl)-1,2,4-triazin-5(4H)-one
• 英文别名: 6-aminomethyl-4H-[1,2,4]triazin-5-one；6-(Aminomethyl)-1,2,4-triazin-5(4H)-one；6-(aminomethyl)-4H-1,2,4-triazin-5-one
• CAS: 867163-25-5
• 化学式: C₄H₆N₄O
• mdl: MFCD19204116
• 分子量: 126.118
• InChiKey: AJILEXBDIMQXQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  79.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(aminomethyl)-1,2,4-triazin-5(4H)-one 、 环丁基甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 cyclobutanecarboxylic acid (5-oxo-4,5-dihydro-[1,2,4]triazin-6-ylmethyl)-amide
  参考文献：
  名称：

  5,7-二取代的咪唑并[5,1- f ] [1,2,4]三嗪-4-胺的合成方法

  摘要：

  5,7-二取代的咪唑并[5,1- f ] [1,2,4]三嗪-4-胺的制备，以5- [3-（苄氧基）苯基] -7-环丁基咪唑并[5,1- ]为例f ] [1,2,4] triazin-4-amine是通过线性和三种收敛合成策略开发的，后者在合成的最后一步为5位多样化提供了最大的灵活性。

  DOI：

  10.1016/j.tetlet.2010.05.083
• 作为产物：
  描述：

  2-((5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)methyl)isoindoline-1,3-dione 在 肼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 6-(aminomethyl)-1,2,4-triazin-5(4H)-one
  参考文献：
  名称：

  5,7-二取代的咪唑并[5,1- f ] [1,2,4]三嗪-4-胺的合成方法

  摘要：

  5,7-二取代的咪唑并[5,1- f ] [1,2,4]三嗪-4-胺的制备，以5- [3-（苄氧基）苯基] -7-环丁基咪唑并[5,1- ]为例f ] [1,2,4] triazin-4-amine是通过线性和三种收敛合成策略开发的，后者在合成的最后一步为5位多样化提供了最大的灵活性。

  DOI：

  10.1016/j.tetlet.2010.05.083

文献信息

• Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
  申请人：Buck A. Elizabeth

  公开号：US20070280928A1

  公开（公告）日：2007-12-06

  The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

  本发明提供了一种治疗患者体内NSCL、胰腺、结肠或乳腺癌肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是mTOR抑制剂，可以附加其他药物或治疗，如其他抗癌药物或放射治疗。本发明还提供了一种治疗患者体内肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是一种能够结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。本发明还提供了一种制药组合物，包括一种能够结合并直接抑制mTORC1和mTORC2激酶的EGFR激酶抑制剂和mTOR抑制剂，以及一种药用载体。本发明中可用于实施该方法的EGFR激酶抑制剂的首选示例是化合物厄洛替尼盐酸盐（也称为TARCEVA®）。
• [EN] 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE HETEROBICYCLIQUES A SUBSTITUTION DE NOYAU BICYCLIQUE 6,6
  申请人：OSI PHARM INC

  公开号：WO2005097800A1

  公开（公告）日：2005-10-20

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein XI, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该式(I)的化合物及其药用可接受的盐，其中XI、X2、X3、X4、X5、X6、X7、R1和Q1在此处定义，抑制IGF-1R酶，可用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病及中枢神经系统疾病和状况。
• Fused bicyclic mTOR inhibitors
  申请人：Chen Xin

  公开号：US20070112005A1

  公开（公告）日：2007-05-17

  Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

  由化学式(I)代表的化合物或其药用可接受的盐，是mTOR的抑制剂，可用于癌症的治疗。
• Imidazotriazines as protein kinase inhibitors
  申请人：Crew Philip Andrew

  公开号：US20060019957A1

  公开（公告）日：2006-01-26

  Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q 1 and R 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

  该公式化合物及其药用可接受的盐，其中Q1和R1在此定义，抑制IGF-1R酶，并可用于治疗和/或预防对酪氨酸激酶抑制治疗有反应的各种疾病和病况。
• [EN] HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE BTK
  申请人：BEIJING INNOCARE PHARMA TECH CO LTD

  公开号：WO2022037649A1

  公开（公告）日：2022-02-24

  Disclosed are heterocyclic compounds of formula (I) or their pharmaceutically acceptable salts used as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. Disclosed also are methods for preparing compounds of formula (I) or their pharmaceutically acceptable salts. Those compounds can be used to treat and/or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases.

  公开了公式（I）的杂环化合物或其药学上可接受的盐，用作Bruton酪氨酸激酶（BTK）及其C481突变体的抑制剂。还公开了制备公式（I）的化合物或其药学上可接受的盐的方法。这些化合物可用于治疗和/或预防由BTK或其C481突变体介导的相关疾病，特别是癌症和自身免疫疾病。